166 related articles for article (PubMed ID: 10959900)
1. MGI 114: augmentation of antitumor activity when combined with topotecan.
Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
[TBL] [Abstract][Full Text] [Related]
2. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
Hammond LA; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Eur J Cancer; 2000 Dec; 36(18):2430-6. PubMed ID: 11094320
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
[TBL] [Abstract][Full Text] [Related]
5. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
[TBL] [Abstract][Full Text] [Related]
6. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
[TBL] [Abstract][Full Text] [Related]
8. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
9. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
[TBL] [Abstract][Full Text] [Related]
10. In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.
Weitman S; Moore R; Barrera H; Cheung NK; Izbicka E; Von Hoff DD
J Pediatr Hematol Oncol; 1998; 20(2):136-9. PubMed ID: 9544164
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
Kelner MJ; McMorris TC; Estes L; Wang W; Samson KM; Taetle R
Invest New Drugs; 1996; 14(2):161-7. PubMed ID: 8913837
[TBL] [Abstract][Full Text] [Related]
12. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.
Kelner MJ; McMorris TC; Estes LA; Oval MY; Rojas RJ; Lynn JR; Lanham KA; Samson KM
Anticancer Drugs; 2000 Mar; 11(3):217-24. PubMed ID: 10831281
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
15. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE; Adamson PC; Nguyen VT; Fox E
Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
18. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
[TBL] [Abstract][Full Text] [Related]
20. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
Van Laar ES; Roth S; Weitman S; MacDonald JR; Waters SJ
Anticancer Res; 2004; 24(1):59-65. PubMed ID: 15015576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
